Pivotal bioVenture Partners Fund I, L.P. 13D and 13G filings for Oculis Holding AG:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I, L.P. | 2,815,476 4.900% | 641,402 (+29.50%) | Filing |
| 2024-12-09 9:43 pm Purchase | 2024-12-03 | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I, L.P. | 2,174,074 5.200% | 141,778 (+6.98%) | Filing |
| 2024-11-07 4:15 pm Sale | 2024-09-30 | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I, L.P. | 2,032,296 4.900% | -382,676 (-15.85%) | Filing |
| 2024-02-12 9:06 pm Sale | 2023-12-31 | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I, L.P. | 2,414,972 7.400% | -617,324 (-20.36%) | Filing |
| 2023-03-15 12:53 pm Purchase | 2023-03-03 | 13G | OCULIS HLDG AG NAMEN AKT OCS | Pivotal bioVenture Partners Fund I, L.P. | 3,032,296 9.300% | 3,032,296 (New Position) | Filing |